Vnitr Lek 2008, 54(3):245-250

The options for preserving reproductive functions in women undergoing cytostatic therapy

P. Němec1,*, M. Huser2, M. Souček1
1 Revmatologická ambulance II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
2 Centrum asistované reprodukce CAR 01 Gynekologicko-porodnické kliniky Lékařské fakulty MU a FN Brno, pracoviště reprodukční medicíny, přednosta prof. MUDr. Pavel Ventruba, DrSc.

The therapy of serious organ damages in systemic connective tissue diseases and systemic vasculitis often requires the use of cytostatics. The serious adverse events associated with such therapy include irreversible damage to the foetal gonadal tissue. Unlike in the case of other fast proliferating tissues of the human body, damage to the ovaries is mostly irreversible, due to the predetermined number of ovarian follicles at birth. Destruction of follicles causes primary ovarian insufficiency and the subsequent sterility with climacteric syndrome symptoms. The issue of preserving ovarian function has not yet been fully resolved. The paper provides an overview of current options for the preservation of reproductive functions in women undergoing cytostatic therapy which include modern techniques of assisted reproduction and new methods of pharmacological protection of the ovaries using gonadoliberin analogues.

Keywords: assisted reproduction; GnRH analogues; sterility; systemic connective tissue disease

Received: December 5, 2007; Accepted: December 28, 2007; Published: March 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Němec P, Huser M, Souček M. The options for preserving reproductive functions in women undergoing cytostatic therapy. Vnitr Lek. 2008;54(3):245-250.
Download citation

References

  1. Lukác J, Rovenský J, Lukácová O et al. Systemic lupus erythematodes. Vnitř Lék 2006; 52: 702-711. Go to PubMed...
  2. Laml T, Schulz-Lobmeyr I, Obruca A et al. Prematureovarian failure: etiology and prospects. Gynecol Endocrinol 2000; 14: 292-302. Go to original source... Go to PubMed...
  3. Ataya K, Rao LV, Laurence E et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in Rhesus monkeys. Biol Reprod 1995; 52: 365-372. Go to original source... Go to PubMed...
  4. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12: 1044-1054. Go to original source... Go to PubMed...
  5. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005; 34: 40-43. Go to original source... Go to PubMed...
  6. Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405. Go to original source... Go to PubMed...
  7. Crha I, Ventruba P, Žáková J et al. Kryokonzervace spermatu před gonadotoxickou léčbou - 11 let zkušeností. Čes Gynek 2007; 72: 320-326.
  8. Boldt J et al. Human oocyte cryopreservation as an adjunct to IVF-embryo transfer cycles. Hum reprod 2003; 18: 1250-1255. Go to original source... Go to PubMed...
  9. Quintans CJ, Donaldson MJ, Bartolino MV et al. Birth of two babies oocytes that were cryopreserved in a choline-based freezing medium. Hum Reprod 2002; 17: 3149-3152. Go to original source... Go to PubMed...
  10. Marrs RP, Greene J, Stone BA. Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos. Am J Obstet Gynecol 2004; 190: 1766-1771. Go to original source... Go to PubMed...
  11. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod 2002; 17: 2787-2794. Go to original source... Go to PubMed...
  12. Meirow D, Fasouliotis SJ, Nugent D et al. A laparoscopic technique for obtaining ovarian cortical biopsy specimens for fertility conservation in patients with cancer. Fertil Steril 1999; 71: 948-951. Go to original source... Go to PubMed...
  13. Donnez J, Bassil S. Indications for cryopreservation of ovarian tissue. Hum Reprod Update 1998; 4: 248-259. Go to original source... Go to PubMed...
  14. Oktay K. Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. Hum Reprod Update 2001; 7: 526-534. Go to original source... Go to PubMed...
  15. Rutherford AJ, Gosden RG. Ovarian tissue cryopreservation: a practical option? Acta Paediatr 1999; 88: 13-18. Go to original source... Go to PubMed...
  16. Hovatta O. Methods for cryopreservation of human ovarian tissue. Reprod Biomed Online 2005; 10: 729-734. Go to original source... Go to PubMed...
  17. Newton H, Aubard Y, Rutherford A et al. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996; 11: 1487-1491. Go to original source... Go to PubMed...
  18. Newton H, Fisher J, Arnold JR et al. Permeation of human ovarian tissue with cryoprotective agents in preparation for cryopreservation. Hum Reprod 1998; 13: 376-380. Go to original source... Go to PubMed...
  19. Gook DA, Edgar DH, Borg J et al. Oocyte maturation, follicle rupture and luteinization in human cryopreserved ovarian tissue following xenografting. Hum Reprod 2003; 18: 1772-1781. Go to original source... Go to PubMed...
  20. Candy CJ, Wood MJ, Whittingham DG. Restoration of a normal reproductive lifespan after grafting of cryopreserved mouse ovaries. Hum Reprod 2000; 15: 1300-1304. Go to original source... Go to PubMed...
  21. Almodin CG, Minguetti-Camara VC, Meister H et al. Recovery of fertility after grafting of cryopreserved germinative tissue in female rabbits following radiotherapy. Hum Reprod 2004; 19: 1287-1293. Go to original source... Go to PubMed...
  22. Candy CJ, Wood MJ, Whittingham DG. Follicular development in cryopreserved marmoset ovarian tissue after transplantation. Hum Reprod 1995; 10: 2334-2338. Go to original source... Go to PubMed...
  23. Kim SS, Yang HW, Kang HG et al. Quantitative assessment of ischemic tissue damage in ovarian cortical tissue with or without antioxidant (ascorbic acid) treatment. Fertil Steril 2004; 82: 679-685. Go to original source... Go to PubMed...
  24. Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 363: 837-840. Go to original source... Go to PubMed...
  25. Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004; 364: 2091-2092. Go to original source... Go to PubMed...
  26. Bedaiwy MA, Falcone T. Ovarian tissue banking for cancer patients: reduction of post-transplantation ischaemic injury: intact ovary freezing and transplantation. Hum Reprod 2004; 19: 1242-1244. Go to original source... Go to PubMed...
  27. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002; 187: 93-105. Go to original source... Go to PubMed...
  28. Practice Committee of the American Society for Reproductive Medicine. Ovarian tissue and oocyte cryopreservation. Fertil Steril 2004; 82: 993-998. Go to original source... Go to PubMed...
  29. Martinez-Madrid B, Dolmans MM, Van Langendockt A et al. Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. Fertil Steril 2004; 82: 1390-1394. Go to original source... Go to PubMed...
  30. Schilsky R, Sherins R, Hubbard S et al. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71: 552-556. Go to original source... Go to PubMed...
  31. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002; 187: 93-105. Go to original source... Go to PubMed...
  32. Blumendfeld Z. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002; 13 (Suppl 1): 138-147. Go to original source... Go to PubMed...
  33. Pritchard KI GnRH analogues and ovarian ablation: their integration in the adjuvant strategy. Recent Results Cancer Res 1998; 152: 285-297.
  34. Manger K, Wildt L, Kalden JR et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2006; 5: 269-272. Go to original source... Go to PubMed...
  35. Mardešić T, Šnajderová M et al. Protocol combining GnRH agonists and GnRH antagonists for rapid supression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004; 25: 90-92. Go to PubMed...
  36. Huser M, Crha I, Hudecek R et al. Ovarian tissue cryopreservation - new opportunity to preserve fertility in female cancer patients. Eur J Gynaecol Oncol 2007; 28: 249-255. Go to PubMed...
  37. Huser M, Višňová H, Ventruba P et al. Možnosti ochrany reprodukčních funkcí u žen podstupujících chemoterapii pro hematologickou malignitu. Prakt Gyn 2006; 9: 6-8.
  38. Huser M, Juránková E, Crha I et al. Kryokonzervace ovariální tkáně - šance na záchranu fertility žen s nádorovým onemocněním. Čes Gynek 2007; 72: 68-73.
  39. Paynter SJ. Current status of the cryopreservation of human unfertilized oocytes. Human Reprod Update 2000; 6: 449-456. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.